Asset Details
Do you wish to reserve the book?
Growth hormone deficiency testing and treatment following mild traumatic brain injury
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Growth hormone deficiency testing and treatment following mild traumatic brain injury
Do you wish to request the book?
Growth hormone deficiency testing and treatment following mild traumatic brain injury
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Growth hormone deficiency testing and treatment following mild traumatic brain injury
2021
Overview
Pituitary dysfunction, specifically growth hormone (GH) deficiency, can occur following traumatic brain injury. Our objective was to characterize the prevalence of GH deficiency (GHD) testing and response to recombinant human GH (rhGH) treatment in adults with persistent symptoms following mild traumatic brain injury (mTBI) referred for assessment of pituitary dysfunction. A retrospective chart review was conducted of patients seen at an outpatient brain injury clinic with a diagnosis of mTBI and persistent post-concussive symptoms who were referred to endocrinology. Clinical assessments of symptoms were collected. Investigations and results of GHD were collected, including initiation of rhGH treatment and treatment response. Of the 253 patients seen in both brain injury and endocrinology clinics, 97 with mTBI were referred for investigation of pituitary dysfunction and 73 (75%) had dynamic testing for assessment of GHD. Of the 26 individuals diagnosed with GHD, 23 (88%) started rhGH. GH therapy was inconsistently offered based on interpretation of GH dynamic testing results. Of those who started rhGH, 18 (78%) had a useful treatment response. This study suggests that clinical management of these patients is varied, highlighting a need for clear guidelines for the diagnosis and management of GHD following mTBI.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adult
/ Brain Concussion - metabolism
/ Female
/ Growth Disorders - diagnosis
/ Growth Disorders - drug therapy
/ Human Growth Hormone - blood
/ Human Growth Hormone - deficiency
/ Human Growth Hormone - therapeutic use
/ Humanities and Social Sciences
/ Humans
/ Insulin-Like Growth Factor I - metabolism
/ Male
/ Patients
/ Post-Concussion Syndrome - metabolism
/ Science
We currently cannot retrieve any items related to this title. Kindly check back at a later time.